A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma

Ye-Lin Liang,Yuan Zhang,Xi-Rong Tan,Han Qiao,Song-Ran Liu,Ling-Long Tang,Yan-Ping Mao,Lei Chen,Wen-Fei Li,Guan-Qun Zhou,Yin Zhao,Jun-Yan Li,Qian Li,Sheng-Yan Huang,Sha Gong,Zi-Qi Zheng,Zhi-Xuan Li,Ying Sun,Wei Jiang,Jun Ma,Ying-Qin Li,Na Liu
DOI: https://doi.org/10.1038/s41467-022-30709-6
IF: 16.6
2022-05-30
Nature Communications
Abstract:Abstract Increasing evidence has revealed the roles of long noncoding RNAs (lncRNAs) as tumor biomarkers. Here, we introduce an immune-associated nine-lncRNA signature for predicting distant metastasis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The nine lncRNAs are identified through microarray profiling, followed by RT–qPCR validation and selection using a machine learning method in the training cohort ( n = 177). This nine-lncRNA signature classifies patients into high and low risk groups, which have significantly different distant metastasis-free survival. Validations in the Guangzhou internal ( n = 177) and Guilin external ( n = 150) cohorts yield similar results, confirming that the signature is an independent risk factor for distant metastasis and outperforms anatomy-based metrics in identifying patients with high metastatic risk. Integrative analyses show that this nine-lncRNA signature correlates with immune activity and lymphocyte infiltration, which is validated by digital pathology. Our results suggest that the immune-associated nine-lncRNA signature can serve as a promising biomarker for metastasis prediction in LA-NPC.
multidisciplinary sciences
What problem does this paper attempt to address?